Angiogenesis: The new potential target for the therapy of psoriasis?

Drug News and Perspectives

Volumn 21, Issue 2, 2008, Pages 97-105

  Heidenreich, Regina ^a,b   Röcken, Martin ^a   Ghoreschi, Kamran ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AE 941; ANGIOPOIETIN; CALCITRIOL; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; INTERLEUKIN 8; METHOTREXATE; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; COMPREHENSION; HUMAN; INFLAMMATORY DISEASE; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW;

ANGIOPOIETINS; ANIMALS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 43049148701     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.2.1188196     Document Type: Review

References (96)

1. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386: 671-4.
2. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6(4): 389-95.
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1): 27-31.
4. Ghoreschi, K., Mrowietz, U. and Rocken, M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003, 81(8): 471-80.
5. Zenz, R., Eferl, R., Kenner, L. et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437(7057): 369-75.
6. Rebholz, B., Haase, I., Eckelt, B. et al. Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity 2007, 27(2): 296-307.
7. Nicolas, J.F., Chamchick, N., Thivolet, J., Wijdenes, J., Morel, P. and Revillard, J.P. CD4 antibody treatment of severe psoriasis. Lancet 1991, 338(8762): 321.
8. Prinz, J., Braun-Falco, O., Meurer, M. et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991, 338(8762): 320-1.
9. Nickoloff, B.J. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: Human skin model of psoriasis. J Investig Dermatol Symp Proc 2000, 5(1): 67-73.
10. Ghoreschi, K., Thomas, P., Breit, S. et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003, 9(1): 40-6.
11. Ghoreschi, K., Weigert, C. and Rocken, M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007, 25(6): 574-80.
12. Folkman, J. Angiogenesis in psoriasis: Therapeutic implications. J Invest Dermatol 1972, 59(1): 40-3.
13. Telner, P. and Fekete, Z. The capillary responses in psoriatic skin. J Invest Dermatol 1961, 36: 225-30.
14. Kulka, J.P. Microcirculatory impairment as a factor in inflammatory tissue damage. Ann N Y Acad Sci 1964, 116: 1018-44.
15. Goodfield, M., Hull, S.M., Holland, D. et al. Investigations of the 'active' edge of plaque psoriasis: Vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 1994, 131(6): 808-13.
16. Creamer, D., Allen, M.H., Sousa, A., Poston, R. and Barker, J.N. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997, 136(6): 859-65.
17. Ragaz, A. and Ackerman, A.B. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1979, 1(3): 199-214.
18. Braverman, I.M. and Sibley, J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982, 78(1): 12-7.
19. Braverman, I.M. and Yen, A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977, 68(1): 53-60.
20. Griffiths, C.E., Voorhees, J.J. and Nickoloff, B.J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989, 20(4): 617-29.
21. Groves, R.W., Allen, M.H., Barker, J.N., Haskard, D.O. and MacDonald, D.M. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 1991, 124(2): 117-23.
22. Groves, R.W., Ross, E.L., Barker, J.N. and MacDonald, D.M. Vascular cell adhesion molecule-1: Expression in normal and diseased skin and regulation in vivo by interferon gamma. J Am Acad Dermatol 1993, 29(1): 67-72.
23. Jin, H. and Varner, J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004, 90(3): 561-5.
24. Brooks, P.C., Clark, R.A. and Cheresh, D.A. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science 1994, 264(5158): 569-71.
25. Kim, S., Bell, K., Mousa, S.A. and Varner, J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000, 156(4): 1345-62.
26. Creamer, J.D. and Barker, J.N. Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 1995, 20(1): 6-9.
27. Nickoloff, B.J., Mitra, R.S., Varani, J., Dixit, V.M. and Polverini, P.J. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994, 144(4): 820-8.
28. Creamer, D., Sullivan, D., Bicknell, R. and Barker, J. Angiogenesis in psoriasis. Angiogenesis 2002, 5(4): 231-6.
29. Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis (Review). Am J Pathol 1995, 146(5): 1029-39.
30. De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. and Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255(5047): 989-91.
31. Shibuya, M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995, 67: 281-316.
32. Shibuya, M. and Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5): 549-60.
33. Ferrara, N., Gerber, H.P. and LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6): 669-76.
34. Detmar, M., Brown, L.F., Claffey, K.P. et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994, 180(3): 1141-6.
35. Bhushan, M., McLaughlin, B., Weiss, J.B. and Griffiths, C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999, 141(6): 1054-60.
36. Creamer, D., Allen, M.H, Groves, R.W. and Barker, J.N. Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 1996, 348(9034): 1101.
37. Nielsen, H.J., Christensen, I.J., Svendsen, M.N. et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002, 51(11): 563-7.
38. Goedkoop, A.Y., Kraan, M.C., Picavet, D.I. et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: A prospective single-centre study. Arthritis Res Ther 2004, 6(4): R326-34.
39. Young, H.S., Summers, A.M., Bhushan, M., Brenchley, P.E. and Griffiths, C.E. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004, 122(1): 209-15.
40. Young, H.S., Summers, A.M., Read, I.R. et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006, 126(2): 453-9.
41. Xia, Y.P., Li, B., Hylton, D., Detmar, M., Yancopoulos, G.D. and Rudge, J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003, 102(1): 161-8.
42. Levy, A.P., Levy, N.S., Wegner, S. and Goldberg, M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270(22): 13333-40.
43. Liu, Y., Cox, S.R., Morita, T. and Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995, 77(3): 638-43.
44. Wang, G.L., Jiang, B.H., Rue, E.A. and Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92(12): 5510-4.
45. Forsythe, J.A., Jiang, B.H., Iyer, N.V. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9): 4604-13.
46. Gerber, H.P., Condorelli, F., Park, J. and Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997, 272(38): 23659-67.
47. Harris, A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1): 38-47.
48. Maxwell, P.H. and Ratcliffe, P.J. Oxygen sensors and angiogenesis. Sem Cell Dev Biol 2002, 13: 29-37.
49. Wenger, R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002, 16(10): 1151-62.
50. Rosenberger, C., Solovan, C., Rosenberger, A.D. et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Invest Dermatol 2007, 127(10): 2445-52.
51. Tovar-Castillo, L.E., Cancino-Diaz, J.C., Garcia-Vazquez, F. et al. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol 2007, 46(3): 239-46.
52. Johansen, C., Funding, A.T., Otkjaer, K. et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006, 176(3): 1431-8.
53. Frater-Schroder, M., Risau, W., Hallmann, R., Gautschi, P. and Bohlen, P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987, 84(15): 5277-81.
54. Fajardo, L.F., Kwan, H.H., Kowalski, J., Prionas, S.D. and Allison, A.C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992, 140(3): 539-44.
55. Montrucchio, G., Lupia, E., Battaglia, E. et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 1994, 180(1): 377-82.
56. Patterson, C., Perrella, M.A., Endege, W.O., Yoshizumi, M., Lee, M.E. and Haber, E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 1996, 98(2): 490-6.
57. Yoshida, S., Ono, M., Shono, T. et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997, 17(7): 4015-23.
58. Goukassian, D.A., Qin, G., Dolan, C. et al. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007, 115(6): 752-62.
59. Schroder, J.M. and Christophers, E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986, 87(1): 53-8.
60. Biedermann, T., Kneilling, M., Mailhammer, R. et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000, 192(10): 1441-52.
61. Schulz, B.S., Michel, G., Wagner, S. et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993, 151(8): 4399-406.
62. Duan, H., Koga, T., Kohda, F., Hara, H., Urabe, K. and Furue, M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001, 26(2): 119-24.
63. Middleton, J., Neil, S., Wintle, J. et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997, 91(3): 385-95.
64. Tuschil, A., Lam, C., Haslberger, A. and Lindley, I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992, 99(3): 294-8.
65. Li, A., Dubey, S., Varney, M.L., Dave, B.J. and Singh, R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170(6): 3369-76.
66. Dumont, D.J., Gradwohl, G., Fong, G.H. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994, 8(16): 1897-909.
67. Sato, T.N., Tozawa, Y., Deutsch, U. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376(6535): 70-4.
68. Davis, S., Aldrich, T.H., Jones, P.F. et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [see comments]. Cell 1996, 87(7): 1161-9.
69. Suri, C., Jones, P.F., Patan, S. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]. Cell 1996, 87(7): 1171-80.
70. Maisonpierre, P.C., Suri, C., Jones, P.F. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322): 55-60.
71. Wong, A.L., Haroon, Z.A., Werner, S., Dewhirst, M.W., Greenberg, C.S. and Peters, K.G. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997, 81(4): 567-74.
72. Kuroda, K., Sapadin, A., Shoji, T., Fleischmajer, R. and Lebwohl, M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001, 116(5): 713-20.
73. Fiedler, U., Reiss, Y., Scharpfenecker, M. et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12(2): 235-9.
74. Rao, A., Luo, C. and Hogan, P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15: 707-47.
75. Al-Daraji, W.I., Grant, K.R., Ryan, K., Saxton, A. and Reynolds, N.J. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002, 118(5): 779-88.
76. Hernandez, G.L., Volpert, O.V., Iniguez, M.A. et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001, 193(5): 607-20.
77. Schuerwegh, A.J., van Offel, J.F., Bridts, C.H., Stevens, W.J. and De Clerck, L.S. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001, 28(8): 1793-9.
78. Hirata, S., Matsubara, T., Saura, R., Tateishi, H. and Hirohata, K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989, 32(9): 1065-73.
79. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K. and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996, 93(5): 1831-5.
80. Yamasaki, E., Soma, Y., Kawa, Y. and Mizoguchi, M. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol 2003, 149(1): 30-8.
81. Oikawa, T., Hirotani, K., Ogasawara, H. et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990, 178(2): 247-50.
82. Oh, C.J., Das, K.M. and Gottlieb, A.B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000, 42(5 Pt. 1): 829-30.
83. Chaudhari, U., Romano, P., Mulcahy, L.D., Dooley, L.T., Baker, D.G. and Gottlieb, A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A ran demised trial. Lancet 2001, 357(9271): 1842-7.
84. Gottlieb, A.B. Infliximab for psoriasis. J Am Acad Dermatol 2003, 49(Suppl. 2): S112-7.
85. Cordiali-Fei, P., Trento, E., D'Agosto, G. et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis 2006, 3: 5.
86. Markham, T., Mullan, R., Golden-Mason, L. et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006, 54(6): 1003-12.
87. Canete, J.D., Pablos, J.L., Sanmarti, R. et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50(5): 1636-41.
88. Mastroianni, A., Minutilli, E., Mussi, A. et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005, 153(3): 531-6.
89. Aggarwal, A., Panda, S. and Misra, R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: A time kinetic study. Ann Rheum Dis 2004, 63(7): 891-2.
90. Loewe, R., Holnthoner, W., Groger, M. et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002, 168(9): 4781-7.
91. Sauder, D.N., Dekoven, J., Champagne, P., Croteau, D. and Dupont, E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002, 47(4): 535-41.
92. Dupont, E., Falardeau, P., Mousa, S.A. et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002, 19(2): 145-53.
93. Keshtgarpour, M. and Dudek, A.Z. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007, 149(3): 103-6.
94. Kerbel, R. and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2(10): 727-39.
95. Faivre, S., Delbaldo, C., Vera, K. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, inpatients with cancer. J Clin Oncol 2006, 24(1): 25-35.
96. Pichler, B.J., Kneilling, M., Haubner, R. et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med 2005, 46(1): 184-9.